文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

使用18F-DCFPyL前列腺特异性膜抗原引导的正电子发射断层扫描/磁共振成像定义前列腺立体定向体部放疗的腺体内推量

Using 18F-DCFPyL Prostate-Specific Membrane Antigen-Directed Positron Emission Tomography/Magnetic Resonance Imaging to Define Intraprostatic Boosts for Prostate Stereotactic Body Radiation Therapy.
PubMed 文献 · Adv Radiat Oncol · 2023-04-09

该研究纳入13例局限期前列腺癌患者,在前瞻性影像试验中于根治性治疗前接受18F-DCFPyL PET/MRI检查,评估PET与MRI所见病灶的一致性,并比较仅用MRI病灶、仅用PET病灶及联合PET/MRI病灶制定前列腺SBRT计划的靶区覆盖与直肠、尿道剂量。结果显示53.8%(21/39)病灶在PET与MRI间不一致,PET单独发现12个病灶、MRI单独发现9个;使用全部病灶定义腺体内推量可获得最佳覆盖且不违反直肠和尿道约束。

要点

  • 多数病灶(21/39,53.8%)在PET与MRI间不一致,PET单独发现12个、MRI单独发现9个。
  • 一致病灶中仍有不重叠区域,平均Dice系数为0.34。
  • 使用全部病灶定义腺体内推量的SBRT计划覆盖最佳且未违反直肠和尿道约束。

核心结论

  • 作者认为同时使用多参数MRI和PSMA引导PET可能更好地识别前列腺内全部大体病灶,联合两种影像可能改善腺体内推量的计划制定。

研究设计与样本

  • 研究纳入13例局限期前列腺癌患者,均在一项前瞻性影像试验中于根治性治疗前接受18F-DCFPyL PET/MRI检查。
  • 评估PET与MRI所见病灶的一致(重叠)与不一致(不重叠)数量,并用Dice和Jaccard相似系数评估一致病灶的重叠程度。
  • 将PET/MRI影像与同日获得的CT扫描融合制定前列腺SBRT计划,分别基于仅MRI病灶、仅PET病灶及联合PET/MRI病灶。

主要发现

  • 多数病灶(21/39,53.8%)在MRI与PET间不一致,PET单独发现12个病灶、MRI单独发现9个病灶。
  • 在PET与MRI一致的病灶中,仍有区域在两次扫描间不重叠,平均Dice系数为0.34。
  • 使用全部病灶定义腺体内推量的前列腺SBRT计划对所有病灶覆盖最佳,且未违反直肠和尿道约束。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The recently reported FLAME trial demonstrated a biochemical disease-free survival benefit to using a focal intraprostatic boost to multiparametric magnetic resonance imaging (mpMRI)-identified lesions in men with localized prostate cancer treated with definitive radiation therapy. Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) may identify additional areas of disease. In this work, we investigated using both PSMA PET and mpMRI in planning focal intraprostatic boosts using stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: We evaluated a cohort of patients (n = 13) with localized prostate cancer who were imaged with 2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-2-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid (18F-DCFPyL) PET/MRI on a prospective imaging trial before undergoing definitive therapy. The number of lesions concordant (overlapping) and discordant (no overlap) on PET and MRI was assessed. Overlap between concordant lesions was evaluated using the Dice and Jaccard similarity coefficients. Prostate SBRT plans were created fusing the PET/MRI imaging to computed tomography scans acquired the same day. Plans were created using only MRI-identified lesions, only PET-identified lesions, and the combined PET/MRI lesions. Coverage of the intraprostatic lesions and doses to the rectum and urethra were assessed for each of these plans. RESULTS: The majority of lesions (21/39, 53.8%) were discordant between MRI and PET, with more lesions seen by PET alone (12) than MRI alone (9). Of lesions that were concordant between PET and MRI, there were still areas that did not overlap between scans (average Dice coefficient, 0.34). Prostate SBRT planning using all lesions to define a focal intraprostatic boost provided the best coverage of all lesions without compromising constraints on the rectum and urethra. CONCLUSIONS: Using both mpMRI and PSMA-directed PET may better identify all areas of gross disease within the prostate. Using both imaging modalities could improve the planning of focal intraprostatic boosts.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Floberg JM, Wells SA, Ojala D, et al. Using 18F-DCFPyL Prostate-Specific Membrane Antigen-Directed Positron Emission Tomography/Magnetic Resonance Imaging to Define Intraprostatic Boosts for Prostate Stereotactic Body Radiation Therapy. Adv Radiat Oncol. 2023. PMID: 37250282. doi:10.1016/j.adro.2023.101241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。